In short
This article provides an overview of clinical trials investigating the use of MK-0482 (rolistobart) in patients with advanced non-small cell lung cancer (NSCLC). These trials are part of the KEYMAKER-U01 study, which aims to evaluate the safety and efficacy of MK-0482 in combination with other treatments for NSCLC patients at various stages of their disease journey.
At a glance
- Study Drug
- MK-0482 (rolistobart)
- Cancer Type
- Advanced Non-Small Cell Lung Cancer (NSCLC)
- Study Design
- Phase 2, umbrella study with rolling arms
- Patient Populations
- Treatment-naive, PD-L1 positive, and PD-(L)1 refractory NSCLC patients
- Primary Objective
- Estimate Objective Response Rate (ORR)
- Secondary Objectives
- Estimate Progression-Free Survival (PFS), evaluate safety and tolerability
- Key Eligibility Criteria
- Stage IV NSCLC, ability to provide tumor tissue sample, specific criteria for each substudy
- Treatment Combinations
- MK-0482 with pembrolizumab, with or without chemotherapy
- Safety Monitoring
- Adverse events, discontinuation due to adverse events
- Maximum Daily Dose
- 750 mg of MK-0482
- Maximum Treatment Period
- 105 days
What is MK-0482 (Rolistobart)?
MK-0482, also known as Rolistobart, is an investigational drug being studied for the treatment of advanced non-small cell lung cancer (NSCLC). It is a biological agent developed by Merck & Co., Inc. and is currently undergoing clinical trials to evaluate its safety and effectiveness in treating NSCLC patients.
How Does MK-0482 Work?
While the exact mechanism of action is not fully disclosed in the available information, MK-0482 is being studied in combination with other cancer treatments, particularly pembrolizumab, an immunotherapy drug. This combination approach suggests that MK-0482 may work by enhancing the body's immune response against cancer cells or by targeting specific pathways involved in cancer growth.
Clinical Trials Involving MK-0482
MK-0482 is being investigated in several clinical trials as part of the KEYMAKER-U01 study. These trials are designed to evaluate the drug's effectiveness in different scenarios:
- In combination with pembrolizumab and chemotherapy for patients who have not received prior treatment for advanced NSCLC.
- In combination with pembrolizumab for patients with PD-L1 positive advanced NSCLC who have not received prior treatment.
- In combination with pembrolizumab for patients with advanced NSCLC who have previously been treated with anti-PD-(L)1 therapy.
Potential Benefits of MK-0482
The main goals of the MK-0482 clinical trials are to:
- Improve the objective response rate (ORR), which measures how well tumors respond to treatment.
- Increase progression-free survival (PFS), which is the length of time during and after treatment that a patient lives with cancer without it worsening.
- Provide a new treatment option for patients whose cancer has become resistant to existing therapies.
How is MK-0482 Administered?
MK-0482 is administered as a solution for intravenous infusion. This means it is given directly into the bloodstream through a vein. The maximum daily dose being studied is 750 mg, with a total treatment period of up to 105 days.
Possible Side Effects
As with any investigational drug, the full range of side effects is not yet known. The clinical trials are designed to evaluate the safety and tolerability of MK-0482 in combination with other treatments. Patients in the trials will be closely monitored for any adverse events.
Who May Be Eligible for MK-0482 Treatment?
Eligibility criteria for the MK-0482 clinical trials include:
- Patients with confirmed Stage IV squamous or non-squamous NSCLC.
- Patients who have not received prior systemic treatment for metastatic NSCLC (for some trials).
- Patients who have progressed on previous anti-PD-(L)1 therapy (for specific trials).
- Patients with adequate organ function and who meet other specific health criteria.
Future Research and Considerations
As MK-0482 is still in the investigational stage, more research is needed to fully understand its effectiveness and safety profile. The ongoing clinical trials will provide valuable information about how well the drug works in different patient populations and in combination with other treatments. Patients interested in participating in these trials should discuss the potential risks and benefits with their healthcare providers.